Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)
Incyte Corporation
Incyte Corporation
Trishula Therapeutics, Inc.
Spanish Oncology Genito-Urinary Group
Actuate Therapeutics Inc.
Altor BioScience
The University of Texas Health Science Center, Houston
Altor BioScience
Massachusetts General Hospital
Pierre Fabre Medicament
Bristol-Myers Squibb
Dana-Farber Cancer Institute
University of Kentucky
Eli Lilly and Company